Aquestive Therapeutics Inc (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercialising differentiated products that meet patients' unmet needs and solve therapeutic problems, announced yesterday its financial results for the first quarter ended 31 March 2019.

The company reported total revenues of USD12.6m in the first quarter 2019 compared to USD23.4m in the first quarter of 2018.

The firm's net loss for the first quarter 2019 was USD14.7m or USD0.59 loss per share.

Keith J Kendall, Aquestive chief executive officer, said, 'We started the year focused on the commercial, regulatory and development milestones that we believe will catalyse our growth and bring value to shareholders. We are progressing as planned across our key initiatives, including the launch of Sympazan, the initiation and execution of a crossover study for Libervant, agreeing with the FDA to move forward with the NDA filing process for that asset, as well as the initiation of the Phase 1 Proof of Concept study for AQST-108.'